Warfarin Label Change Falls Short of Recommending Genetic Testing
Executive Summary
FDA took warfarin one step into the world of personalized medicine Aug. 16 with labeling changes that inform patients and doctors about the usefulness of genetic testing before beginning therapy with the blood thinner
You may also be interested in...
Genomic Tests For Warfarin Could Gain Coverage With Study Participation
Under a CMS proposal, genomic testing to predict warfarin response would receive Medicare coverage in the context of a clinical trial comparing the frequency of five kinds of adverse events with and without the tests.
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor